Literature DB >> 24385267

Influence of high-normal serum TSH levels on major cardiovascular risk factors and Visceral Adiposity Index in euthyroid type 2 diabetic subjects.

A Giandalia1, G T Russo, E L Romeo, A Alibrandi, P Villari, A A Mirto, G Armentano, S Benvenga, D Cucinotta.   

Abstract

Although several observations indicate that serum TSH levels in the high normal range are related to cardiovascular (CVD) risk factors in the general population, similar data are limited in diabetic subjects. The aim of this study was to investigate the potential associations between TSH serum levels within the normal range and major metabolic and non-metabolic CVD risk factors in a cohort of euthyroid type 2 diabetic subjects. Thyroid hormones, TSH levels, anthropometric parameters, lipid profile, glucose control, and blood pressure were measured in 490 euthyroid type 2 diabetic subjects, consecutively attending two outpatient diabetic units in Southern Italy. In all subjects, we also calculated the Visceral Adiposity Index (VAI), an obesity-related index associated with CVD risk. Diabetic women showed higher mean serum TSH levels and lower FT4 concentration than diabetic men, while FT3 levels were comparable in the two genders. Stratifying the study population according to quartiles of TSH levels, subjects in the highest TSH quartile were more likely to be female and younger, with higher values of BMI and waist circumference (P = 0.05 both), higher triglycerides (P = 0.002) and non-HDL cholesterol concentrations (P = 0.01), higher VAI values (P = 0.02), and lower FT4 levels (P = 0.05), when compared to those in the lowest quartile. At multivariate analysis, a younger age, female gender, triglycerides levels, and waist circumference were independently associated with higher TSH levels. In conclusion, in type 2 diabetic subjects with no evidence of thyroid disease, higher TSH concentrations within the normal range were more frequent in women and in younger subjects, and they were associated with visceral obesity and higher triglycerides concentrations, two well-known CVD risk factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385267     DOI: 10.1007/s12020-013-0137-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  38 in total

1.  Thyreotropin levels in diabetic patients on metformin treatment.

Authors:  Carlo Cappelli; Mario Rotondi; Ilenia Pirola; Barbara Agosti; Annamaria Formenti; Emanuela Zarra; Umberto Valentini; Paola Leporati; Luca Chiovato; Maurizio Castellano
Journal:  Eur J Endocrinol       Date:  2012-05-29       Impact factor: 6.664

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex.

Authors: 
Journal:  Diabetes Care       Date:  1997-11       Impact factor: 19.112

4.  Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study.

Authors:  S A P Chubb; W A Davis; T M E Davis
Journal:  J Clin Endocrinol Metab       Date:  2005-06-28       Impact factor: 5.958

Review 5.  The interface between thyroid and diabetes mellitus.

Authors:  Leonidas H Duntas; Jacques Orgiazzi; Georg Brabant
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

6.  Value of baseline serum thyrotropin as a predictor of hypothyroidism in patients with diabetes mellitus.

Authors:  Vijay Ramasamy; Raghu Kadiyala; Faisal Fayyaz; Akhila Mallipedhi; Piero Baglioni; Onyebuchi E Okosieme
Journal:  Endocr Pract       Date:  2011 Jan-Feb       Impact factor: 3.443

7.  Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women.

Authors:  Hyun Tae Park; Geum Joon Cho; Ki Hoon Ahn; Jung Ho Shin; Soon Cheol Hong; Tak Kim; Jun Young Hur; Young Tae Kim; Kyu Wan Lee; Sun Haeng Kim
Journal:  Maturitas       Date:  2009-02-27       Impact factor: 4.342

8.  Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study.

Authors:  Bozorgmanesh Mohammadreza; Hadaegh Farzad; Khalili Davoud; Azizi Fereidoun Fereidoun Prof
Journal:  Cardiovasc Diabetol       Date:  2012-03-07       Impact factor: 9.951

9.  The Relationship between Type 2 Diabetes Mellitus and Related Thyroid Diseases.

Authors:  Chaoxun Wang
Journal:  J Diabetes Res       Date:  2013-04-04       Impact factor: 4.011

10.  Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: A cross-sectional study.

Authors:  Katerina Saltiki; Paraskevi Voidonikola; Kimon Stamatelopoulos; Emily Mantzou; Christos Papamichael; Maria Alevizaki
Journal:  Thyroid Res       Date:  2008-09-29
View more
  14 in total

1.  High-normal serum thyrotropin levels and increased glycemic variability in type 2 diabetic patients.

Authors:  Jian-Bin Su; Li-Hua Zhao; Xiu-Lin Zhang; Hong-Li Cai; Hai-Yan Huang; Feng Xu; Tong Chen; Xue-Qin Wang
Journal:  Endocrine       Date:  2018-04-12       Impact factor: 3.633

2.  The prevalence and determinants of hypothyroidism in hospitalized patients with type 2 diabetes mellitus.

Authors:  Fei Song; Cuiping Bao; Meiyu Deng; Hui Xu; Meijuan Fan; Stéphanie Paillard-Borg; Weili Xu; Xiuying Qi
Journal:  Endocrine       Date:  2016-09-07       Impact factor: 3.633

3.  In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia.

Authors:  Elisabetta Morini; Antonino Catalano; Antonino Lasco; Nunziata Morabito; Salvatore Benvenga
Journal:  Endocrine       Date:  2019-03-27       Impact factor: 3.633

4.  Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study.

Authors:  A Albani; F Ferraù; A Ciresi; R Pivonello; C Scaroni; D Iacuaniello; M Zilio; V Guarnotta; A Alibrandi; E Messina; M Boscaro; C Giordano; A Colao; S Cannavo
Journal:  Endocrine       Date:  2018-01-30       Impact factor: 3.633

5.  L-thyroxine malabsorption due to calcium carbonate impairs blood pressure, total cholesterolemia, and fasting glycemia.

Authors:  Elisabetta Morini; Antonino Catalano; Antonino Lasco; Nunziata Morabito; Salvatore Benvenga
Journal:  Endocrine       Date:  2018-10-27       Impact factor: 3.633

6.  Association between lipids profile and thyroid parameters in euthyroid diabetic subjects: a cross-sectional study.

Authors:  Yun Zhang; Ping Lu; Ling Zhang; Xinhua Xiao
Journal:  BMC Endocr Disord       Date:  2015-03-27       Impact factor: 2.763

7.  New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.

Authors:  Xingchun Wang; Jiaqi Chen; Liang Li; Cui Ling Zhu; Jingyang Gao; Sharvan Rampersad; Le Bu; Shen Qu
Journal:  Lipids Health Dis       Date:  2017-04-04       Impact factor: 3.876

8.  Beneficial effects of thyroid hormone on adipose inflammation and insulin sensitivity of obese Wistar rats.

Authors:  Ana C Panveloski-Costa; Caroline Serrano-Nascimento; Paula Bargi-Souza; Leonice L Poyares; Gabriela de S Viana; Maria T Nunes
Journal:  Physiol Rep       Date:  2018-02

Review 9.  The role of thyroid hormone in metabolism and metabolic syndrome.

Authors:  Patrícia de Fátima Dos Santos Teixeira; Patrícia Borges Dos Santos; Carmen Cabanelas Pazos-Moura
Journal:  Ther Adv Endocrinol Metab       Date:  2020-05-13       Impact factor: 3.565

10.  High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes.

Authors:  Ying Tan; Xixiang Tang; Panwei Mu; Yi Yang; Mei Li; Yuanpeng Nie; Haicheng Li; Yanhua Zhu; Yanming Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-22       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.